GGHC
BBIO icon

Gilder Gagnon Howe & Co’s BridgeBio Pharma BBIO Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.2M Sell
420,325
-37,652
-8% -$2.73M 0.37% 71
2025
Q4 		$35M Sell
457,977
-4,334
-0.9% -$284K 0.37% 72
2025
Q3 		$24M Sell
462,311
-3,090
-0.7% -$151K 0.24% 84
2025
Q2 		$20.1M Buy
465,401
+343,158
+281% +$12.5M 0.21% 87
2025
Q1 		$4.23M Buy
122,243
+73,013
+148% +$2.46M 0.06% 142
2024
Q4 		$1.35M Sell
49,230
-182
-0.4% -$4.7K 0.01% 198
2024
Q3 		$1.26M Buy
49,412
+5,110
+12% +$134K 0.02% 200
2024
Q2 		$1.12M Sell
44,302
-997
-2% -$27.3K 0.01% 200
2024
Q1 		$1.4M Buy
45,299
+5,177
+13% +$176K 0.02% 200
2023
Q4 		$1.62M Sell
40,122
-4
-0% -$120 0.02% 190
2023
Q3 		$1.06M Buy
40,126
+4,570
+13% +$130K 0.02% 210
2023
Q2 		$612K Buy
35,556
+3,716
+12% +$55.9K 0.01% 242
2023
Q1 		$528K Sell
31,840
-699
-2% -$8.15K 0.01% 219
2022
Q4 		$248K Sell
32,539
-15,861
-33% -$152K ﹤0.01% 233
2022
Q3 		$481K Sell
48,400
-348
-0.7% -$3.62K 0.01% 221
2022
Q2 		$443K Sell
48,748
-796,327
-94% -$6.66M 0.01% 226
2022
Q1 		$8.58M Sell
845,075
-185
-0% -$1.9K 0.08% 148
2021
Q4 		$14.1M Buy
845,260
+89,938
+12% +$3.81M 0.08% 156
2021
Q3 		$35.4M Sell
755,322
-2,651
-0.3% -$142K 0.18% 121
2021
Q2 		$46.2M Sell
757,973
-6,794
-0.9% -$388K 0.23% 108
2021
Q1 		$47.1M Buy
+764,767
New +$50M 0.25% 103

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gilder Gagnon Howe & Co's BBIO Position: Q1 2026 in Review

Gilder Gagnon Howe & Co reduced its BridgeBio Pharma (BBIO) stake by 8.2% in Q1 2026, selling an estimated $2.73M and leaving 420,325 shares worth $31.2M. The position accounts for 0.37% of the portfolio, ranked #71.

Gilder Gagnon Howe & Co first reported a position in BBIO in Q1 2021 and has held it in 21 quarters since. The position peaked at $47.1M in Q1 2021. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Gilder Gagnon Howe & Co held 420,325 shares of BridgeBio Pharma worth $31.2M as of Q1 2026.
  • Gilder Gagnon Howe & Co sold 37,652 BridgeBio Pharma shares in Q1 2026, an estimated $2.73M.
  • BridgeBio Pharma made up 0.37% of Gilder Gagnon Howe & Co's portfolio in Q1 2026, its #71 holding.
  • Gilder Gagnon Howe & Co first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 21 quarters since.
  • Gilder Gagnon Howe & Co's BridgeBio Pharma position peaked at $47.1M in Q1 2021.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2026, filed 15 May 2026.